From Real-World Data to Improved Outcomes: Examining the Impact of Trastuzumab Disparities on Pathological Complete Response and Long-Term Survival in HER-2 Positive Breast Cancer Patients within the Brazilian Public Health System

被引：0
|
作者：
Antonini, Marcelo
Mattar, Andre
Pannain, Gabriel
Richter, Fernanda Grace Bauk
Amorim, Andressa
Diogenes, Marina
Ferraro, Odair
Gebrim, Luiz
Lopes, Reginaldo Coelho
Real, Juliana
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-16-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-16-06
引用
收藏
页数：4
相关论文
共 46 条
  • [1] Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients
    Guan, Dandan
    Shi, Qingyang
    Zheng, Yajuan
    Zheng, Chaopeng
    Meng, Xuli
    CLINICAL BREAST CANCER, 2024, 24 (05) : 463 - 472.e2
  • [2] Prognostic Factors and Survival Outcomes of Patients With Early HER2+Breast Cancer Treated With Trastuzumab in a Brazilian Public Reference Center: A Real-World Study
    Mattar, Andre
    Hegg, Roberto
    Tayar, Daiane O.
    Rocha, Mauricio
    Terzian, Ana Luisa. B.
    Oliveira, Renato W.
    Julian, Guilherme S.
    Gebrim, Luiz H.
    CLINICAL BREAST CANCER, 2023, 23 (08) : 864 - +
  • [3] Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+early breast cancer: Real-world data from NeoPowER study
    Canino, F.
    Barbolini, M.
    De Giorgi, U. F. F.
    Gianni, L.
    Maestri, A.
    Moscetti, L.
    Omarini, C.
    Zamagni, C.
    Costantini, R. Cuoghi
    Tamburrano, F.
    Antonelli, G.
    Baglio, F.
    Belluzzi, L.
    Martinelli, G.
    Natalizio, S.
    Ponzoni, O.
    Dominici, M.
    Piacentini, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S289 - S290
  • [4] Her-2 positive and TNBC patients receiving neoadjuvant chemotherapy are associated with a high pathological complete response rate - results from real-world outcomes in a multidisciplinary setting
    Rapoport, B. L.
    Smit, T.
    Heyman, L.
    Benn, C. A.
    Nayler, S.
    BREAST, 2021, 56 : S50 - S51
  • [5] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN EARLY HER-2 POSITIVE BREAST CANCER PATIENTS: THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM CASE
    Santos, E. A.
    Saggia, M. G.
    Nasciben, V. D.
    VALUE IN HEALTH, 2008, 11 (06) : A467 - A467
  • [6] Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?
    Calamac, M.
    Stanic, N.
    Djurmez, O.
    Dimitrijevic, M.
    Vukosavljevic, J.
    Serovic, K.
    Oblakovic-Babic, J.
    Minic, I.
    Bozovic-Spasojevic, I.
    BREAST, 2023, 68 : S130 - S131
  • [7] Long-term follow-up of HER2-positive early breast cancer patients with adjuvant trastuzumab: the real-world result and unmet needs
    Shiau, J.
    Fu, O. -Y.
    Wu, C. -C.
    Kan, J. -Y.
    Chen, F. -M.
    Chuang, C. -H.
    Hou, M. -F.
    BREAST, 2019, 44 : S22 - S23
  • [8] Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)
    Benjamin Daniels
    Belinda E. Kiely
    Sarah J. Lord
    Nehmat Houssami
    Christine Y. Lu
    Robyn L. Ward
    Sallie-Anne Pearson
    Breast Cancer Research and Treatment, 2018, 171 : 151 - 159
  • [9] Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)
    Daniels, Benjamin
    Kiely, Belinda E.
    Lord, Sarah J.
    Houssami, Nehmat
    Lu, Christine Y.
    Ward, Robyn L.
    Pearson, Sallie-Anne
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 151 - 159
  • [10] Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database
    Xie, Ling-Xiao
    Liu, Yang
    Yang, Yao-Guo
    Wang, Jing-Nan
    Zhang, Yan-Qun
    Wang, Tao
    Bian, Lu-Yang
    Jiang, Hao
    Su, Xiao-Ming
    Zhou, Yong-Chun
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 489 - 500
12345